NCT04815590

Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose

Pilot Study to Assess the Feasibility, Efficacy and Safety of Extended-release Injectable Buprenorphine for the Treatment of Opioid Use Disorder Among Individuals at High Risk of Overdose

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 40 (estimated)
• Sponsor: BC Centre on Substance Use · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This pilot study will evaluate the feasibility and clinical utility of extended-release injectable buprenorphine (XR-BUP) for the treatment of opioid use disorder (OUD) among individuals at high-risk for overdose (OD).

Detailed description

FASTER-BUP is a 24-week observational pilot study evaluating the feasibility and clinical utility of XR-BUP (brand name: Sublocade) for the treatment of OUD among individuals at high-risk of OD. Forty participants with moderate to severe OUD starting treatment with XR-BUP as part of standard of care will be followed.

Conditions

• Opioid-Use Disorder
• Opioid Overdose

Timeline

• Start date: 2022-10-17
• Primary completion: 2023-10-17
• Completion: 2023-10-17
• First posted: 2021-03-25
• Last updated: 2022-11-17

Locations

1 site across 1 country: Canada